AvalehtABBV • NYSE
add
AbbVie Inc
181,14 $
Pärast sulgemist:(0,20%)+0,36
181,50 $
Suletud: 26. nov, 19:56:10 GMT −5 · USD · NYSE · Välistus
Viimane sulgemishind
177,06 $
Tänane vahemik
176,67 $ - 181,65 $
Aasta vahemik
137,65 $ - 207,32 $
Turuväärtus
319,90 mld USD
Keskmine maht
7,23 mln
P/E suhe
63,20
Dividendimäär
3,62%
Põhibörs
NYSE
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Käive | 14,46 mld | 3,83% |
Põhitegevusega seonduv kulu | 6,07 mld | 21,67% |
Puhastulu | 1,56 mld | −12,20% |
Puhaskasumimarginaal | 10,80 | −15,43% |
Puhaskasum aktsia kohta | 3,00 | 1,69% |
EBITDA | 6,26 mld | −8,02% |
Tõhus maksumäär | 24,95% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 7,28 mld | −45,18% |
Kogu vara | 143,42 mld | 5,29% |
Kõik kohustused | 137,35 mld | 10,68% |
Kogu omakapital | 6,07 mld | — |
Emiteeritud aktsiate arv | 1,77 mld | — |
Hinna ja väärtuse suhe P/B | 51,92 | — |
Varade tasuvus | 7,33% | — |
Kapitali tasuvus | 13,48% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | 1,56 mld | −12,20% |
Põhitegevuse rahakäive | 5,45 mld | −28,08% |
Investeeringute raha | −8,26 mld | −2 137,40% |
Finantseerimise raha | −3,07 mld | −15,45% |
Raha ja raha ekvivalentide muutus | −5,87 mld | −229,70% |
Tasuta rahavoog | 5,50 mld | −26,01% |
Teave
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Asutatud
1. jaan 2013
Veebisait
Töötajate arv
50 000
